CLDX
Celldex Therapeutics Inc
NASDAQ: CLDX · HEALTHCARE · BIOTECHNOLOGY
$32.14
-3.28% today
Updated 2026-04-29
Market cap
$2.52B
P/E ratio
—
P/S ratio
1,632.24x
EPS (TTM)
$-3.90
Dividend yield
—
52W range
$18 – $36
Volume
1.1M
Celldex Therapeutics Inc (CLDX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-12.6%
Last 4 quarters
Revenue YoY growth
-93.6%
Most recent quarter
EPS YoY growth
-71.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+6.4%
2025-11-10
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-02 | $-1.22 | -22.0% | $30.09 | $28.94 | -3.8% |
| 2025-11-10 | $-1.01 | -12.2% | $22.90 | $24.37 | +6.4% |
| 2025-08-07 | $-0.85 | +1.2% | $21.44 | $20.66 | -3.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.00 | $-1.22 | -22.0% | $75000.00 | -93.6% |
| 2025-09-30 | $-0.90 | $-1.01 | -12.2% | — | — |
| 2025-06-30 | $-0.86 | $-0.85 | +1.2% | $730000.00 | -70.8% |
| 2025-03-31 | $-0.69 | $-0.81 | -17.4% | $695000.00 | +345.5% |
| 2024-12-31 | $-0.71 | $-0.71 | +0.6% | $1.18M | -71.6% |
| 2024-09-30 | $-0.67 | $-0.64 | +4.5% | $3.19M | +110.3% |
| 2024-06-30 | $-0.59 | $-0.54 | +8.5% | $2.50M | +832.1% |
| 2024-03-31 | $-0.69 | $-0.56 | +18.8% | $156000.00 | -83.9% |
| 2023-12-31 | $-0.74 | $-0.83 | -12.2% | $4.13M | — |
| 2023-09-30 | $-0.68 | $-0.81 | -19.1% | $1.52M | — |
| 2023-06-30 | $-0.67 | $-0.65 | +3.0% | $268000.00 | — |
| 2023-03-31 | $-0.63 | $-0.62 | +1.6% | $967000.00 | — |
Frequently asked questions
Has Celldex Therapeutics Inc beaten earnings estimates?
Celldex Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -12.6% over the last 4 quarters.
How does CLDX stock react to earnings?
CLDX stock has moved an average of -0.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Celldex Therapeutics Inc's revenue growth rate?
Celldex Therapeutics Inc reported year-over-year revenue growth of -93.6% in its most recent quarter, with EPS growing -71.8% year-over-year.